View source for BioNTech

{{Use dmy dates|date=March 2021}}
{{Infobox company
| name = BioNTech SE
| logo = BioNTech logo.svg
| image_caption = Headquarters in Mainz
| type = [[Public company|Public]] (''[[Societas Europaea|SE]]'')
| traded_as = {{NASDAQ|BNTX}}
| ISIN = {{ISIN|sl=n|pl=y|US09075V1026}}
| industry = [[Biotechnology]]
| founded = {{start date and age|2008}}
| founders = {{Unbulleted list|[[Uğur Şahin]]|[[Özlem Türeci]]|Christoph Huber|[[Andreas Strüngmann]]|[[Thomas Strüngmann]]|Michael Motschmann|Helmut Jeggle}}
| hq_location = 
| hq_location_city = [[Mainz]]
| hq_location_country = Germany
| num_locations = 8
| num_locations_year = 2022
| area_served = Worldwide
| key_people = {{Unbulleted list|[[Uğur Şahin]] (CEO)|[[Özlem Türeci]] (CMO)|Sean Marett (CBO, CCO)|Sierk Poetting (CFO, COO)|Ryan Richardson (CSO)}}
| products = [[BNT162b2]]
| services = [[Immunotherapy]]
| revenue = {{decrease}} {{€|17.3|link=yes}}&nbsp;billion
| revenue_year = 2022
| operating_income = {{decrease}} €12.6&nbsp;billion
| income_year = 2022
| net_income = {{decrease}} €9.43&nbsp;billion
| net_income_year = 2022
| assets = {{increase}} €23.3&nbsp;billion
| assets_year = 2022
| equity = {{increase}} €20.1&nbsp;billion
| equity_year = 2022
| num_employees = {{increase}} 4,530
| num_employees_year = 2022
| website = {{url|biontech.com}}
| footnotes = Biontech FY 2022 report<ref name="FY 2022 report">{{Cite web |url=https://www.sec.gov/ix?doc=/Archives/edgar/data/0001776985/000119312523079791/d377167d20f.htm |title=BioNTech 2022 Annual Report (Form 20-F) |date=27 March 2023 |publisher=[[U.S. Securities and Exchange Commission]] |access-date=24 June 2023}}</ref>
}}
'''BioNTech SE''' ({{IPA|ˈbaɪɒnˌtek}}) is a [[Germany|German]] [[biotechnology]] company dedicated to the creation of active [[Immunotherapy|immunotherapies]] for treatments of serious diseases. 
[[File:Mainz.BioNTechSE.20200731.jpg|thumb|BioNTech headquarters in An der Goldgrube street, [[Mainz]]]]

It researches drugs based on [[messenger RNA]] (mRNA) for use as individualized [[Cancer immunotherapy|cancer immunotherapies]], as [[Vaccine|vaccines]] against [[Infection|infectious]] [[Disease|diseases]] and as [[protein]] replacement therapies for [[Rare disease|rare diseases]].<ref name="SEC report">{{cite report |date=9 September 2019 |title=Form F-1 BioNTech SE |url=https://sec.report/Document/0001193125-19-241112/ |publisher=[[U.S. Securities and Exchange Commission]] |access-date=13 October 2019 |archive-date=14 February 2021 |archive-url=https://web.archive.org/web/20210214094009/https://sec.report/Document/0001193125-19-241112/ |url-status=dead }}</ref> In 2020, the company started developing the BNT162b2 vaccine against [[Severe acute respiratory syndrome coronavirus 2|SARS-CoV-2]] with [[Pfizer]]<ref>{{cite news |last=Lovelace Jr. |first=Berkeley |date=27 July 2020 |title=Pfizer and BioNTech began late-stage human trial for coronavirus vaccine Monday |url=https://www.cnbc.com/2020/07/27/pfizer-and-biontech-began-late-stage-human-trial-for-coronavirus-vaccine-monday.html |work=[[CNBC]] |access-date=2 August 2020}}</ref> and Fosun.<ref>{{cite news |author=<!--Not stated.--> |title=BioNTech in China alliance with Fosun over coronavirus vaccine candidate |url=https://www.reuters.com/article/biontech-fosunpharma-vaccine-collaborati/biontech-in-china-alliance-with-fosun-over-coronavirus-vaccine-candidate-idUSL8N2B90UW |work=[[Reuters]] |location=[[Frankfurt]] |date=15 March 2020 |access-date=2 August 2020}}</ref><ref>{{cite news |last=Burger |first=Ludwig |title=Germany approves trials of COVID-19 vaccine candidate |url=https://www.reuters.com/article/us-health-coronavirus-vaccine-biontech/germany-approves-trials-of-covid-19-vaccine-candidate-idUSKCN2241DN |work=[[Reuters]] |location=[[Berlin]] |date=22 April 2020 |access-date=2 August 2020}}</ref> In late 2020 BioNTech successfully developed, together with Pfizer, the [[RNA vaccine]] called BNT162b2 against COVID-19. The company said, it's vaccine efficacy was 95%. On 2 December 2020, the [[United Kingdom]] government gave permission to use BNT162b2 vaccinations in the country.<ref>{{Cite web|date=2020-12-02|title=UK medicines regulator gives approval for first UK COVID-19 vaccine|url=https://www.gov.uk/government/news/uk-medicines-regulator-gives-approval-for-first-uk-covid-19-vaccine|access-date=2021-01-25|website=GOV.UK|language=en}}</ref> Later in December 2020 USA,<ref>{{Cite journal|last=Commissioner|first=Office of the|date=2021-01-07|title=Pfizer-BioNTech COVID-19 Vaccine Frequently Asked Questions|url=https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/pfizer-biontech-covid-19-vaccine-frequently-asked-questions|journal=FDA|language=en}}</ref> Canada<ref>{{Cite web|last=Canada|first=Health|date=2020-12-09|title=Pfizer-BioNTech COVID-19 vaccine: What you should know|url=https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/pfizer-biontech.html|access-date=2021-01-25|website=aem}}</ref> and the EU<ref>{{Cite web|date=2020-12-21|title=Commission approves BioNTech/Pfizer vaccine|url=https://www.politico.eu/article/european-commission-approves-biontech-pfizer-vaccine/|access-date=2021-01-25|website=POLITICO|language=en-US}}</ref> also gave permission to use the BioNTech vaccine.

== BioNTech Media ==
<gallery widths='160px' heights='100%' mode='traditional' caption=''>
File:Covid19 vaccine biontech pfizer 3.jpg|Pfizer–BioNTech COVID-19 vaccine
</gallery>
== References ==
{{reflist}}

[[Category:2008 establishments in Germany]]
[[Category:Mainz]]
[[Category:Biotechnology companies]]

{{med-stub}}
[[Category:Healthcare companies of Germany]]